Abstract
Ivabradine (Corlanor—Amgen), a first-in-class, hyperpolarizationactivated cyclic nucleotide-gated (HCN) channel blocker, has been approved by FDA for patients with chronic heart failure. This is the first approval of a novel agent for the management of chronic heart failure in nearly a decade. FDA noted that ivabradine was given priority review and granted fast track designation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
